TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin

In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis. Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Quarantine and isolation (CDC) Outcomes before and after Omicron (medRxiv) Infectious viral load in Delta vs Omicron infections (medRxiv) PCR vs rapid antigen test (medRxiv) Booster interval to 5 months (FDA) Cross-reactive memory T cells (Nat Comm) Risk factors for severe outcomes in vaccinated (MMWR) Vaccine effectiveness vs MIS-C (MMWR) Cross-reactive T cells to Omicron from vaccines (medRxiv) Rivaroxiban for thromboprophylaxis (Lancet) Letters read on TWiV 853 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [e-mail]

Source: This Week in Virology - MP3 Edition - January 15, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts